Jim Simons Cellectar Biosciences, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$3.5 - $6.9 $138,950 - $273,930
39,700 Added 31.31%
166,500 $67,000
Q1 2022

May 13, 2022
BUY
$4.6 - $7.8 $31,597 - $53,578
6,869 Added 5.73%
126,800 $87,000
Q4 2021

Feb 11, 2022
SELL
$6.1 - $10.2 $2 Million - $3.34 Million
-327,143 Reduced 73.17%
119,931 $80,000
Q3 2021

Nov 12, 2021
SELL
$8.2 - $12.4 $4.63 Million - $7 Million
-564,194 Reduced 55.79%
447,074 $414,000
Q2 2021

Aug 13, 2021
BUY
$11.8 - $18.2 $1.4 Million - $2.16 Million
118,711 Added 13.3%
1,011,268 $1.2 Million
Q1 2021

May 13, 2021
BUY
$15.2 - $25.0 $9.45 Million - $15.5 Million
621,692 Added 229.52%
892,557 $1.44 Million
Q4 2020

Feb 10, 2021
SELL
$11.2 - $27.7 $1.91 Million - $4.72 Million
-170,462 Reduced 38.62%
270,865 $563,000
Q3 2020

Nov 13, 2020
SELL
$10.6 - $16.6 $3.7 Million - $5.8 Million
-349,275 Reduced 44.18%
441,327 $547,000
Q2 2020

Aug 13, 2020
BUY
$10.3 - $17.3 $5.75 Million - $9.66 Million
558,500 Added 240.63%
790,602 $1.01 Million
Q1 2020

May 14, 2020
BUY
$11.0 - $31.7 $364,100 - $1.05 Million
33,100 Added 16.63%
232,102 $309,000
Q4 2019

Feb 13, 2020
BUY
$10.6 - $24.1 $234,260 - $532,610
22,100 Added 12.49%
199,002 $448,000
Q3 2019

Nov 13, 2019
BUY
$20.0 - $24.6 $1.08 Million - $1.32 Million
53,854 Added 43.77%
176,902 $354,000
Q2 2019

Aug 12, 2019
BUY
$18.6 - $28.2 $1.23 Million - $1.87 Million
66,300 Added 116.83%
123,048 $268,000
Q1 2019

May 14, 2019
SELL
$15.8 - $28.5 $4,740 - $8,550
-300 Reduced 0.53%
56,748 $133,000
Q4 2018

Feb 13, 2019
BUY
$12.9 - $36.9 $735,919 - $2.11 Million
57,048 New
57,048 $88,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $9.6M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email